Risk-Sharing Arrangements: Greater Transparency Can Enhance “Public Good” – ISPOR Draft Report
Executive Summary
The expense of conducting a good risk-sharing arrangement between a product’s manufacturer and a payer makes it even more important that results of an evaluation be made public, so that others can benefit from the findings, an ISPOR task force suggests.
You may also be interested in...
Risk-Sharing Drug Rebate Contracts: Do They Live Up To The Hype?
Manufacturers and payers will continue to work on innovative pricing arrangements, roundtable panelists said, but they are likely to be less complex and resource intensive than many of the risk-sharing contracts announced to date, particularly in Europe.
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.
FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Khan Says
The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.